Therapeutic effectiveness of bacteriophage in the treatment of pneumonia caused by NDM-4 producing in a mouse model
Abstract
Exploration for an alternative to antibiotics to treat bacterial diseases is becoming more important due to the emergence of antibiotic resistance. Bacteriophage or phage has been used for the treatment of superficial infections. In this study, phage isolated from the environment was used as a therapeutic agent against NDM-producing causing respiratory disease in an experimental mouse model. The isolated phage was found to belong to the family based on morphology. For experiments, five groups of mice were used including infection-free, phage-only, bacteria-infected, and the other two groups infected with and treated either with an antibiotic, levofloxacin (50 mg/kg, twice a day intraperitoneally) or phage (3×10 PFU/mL). All the animals were observed for 72 hours for mortality, and the surviving mice were killed for analysis. In the infected group, pneumonia was developed after 48 hours, and 8/10 animals were dead after 72 hours. When pneumonia infected mice were treated with an antibiotic, levofloxacin all the animals survived but showed the signs of pneumonia, and there was up to 6 log CFU/g±0.82 reduction in the bacterial count. In phage treated group, all the animals survived at the end of 72 hours and all the animals were healthy with no signs of pneumonia. The experiment showed new insights into the biology of the broad host range of phage, demonstrating that phage has prospects for the treatment of pneumonia caused by the NDM-producing .
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.